Skip to Content

CymaBay Therapeutics, Inc. (NASDAQ: CBAY)

Securities Class Action

  • Date:
  • 3/3/2020
  • Company Name:
  • CymaBay Therapeutics, Inc.
  • Stock Symbol:
  • CBAY
  • Status:
  • Investigating

Case Finder

Locate any case using the tools below.

NEW YORK, March 3, 2020 –Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against CymaBay Therapeutics, Inc. (NASDAQ: CBAY) on behalf of CymaBay stockholders. Our investigation concerns whether CymaBay has violated the federal securities laws and/or engaged in other unlawful business practices.

On January 29, 2020, CymaBay announced in a letter from its President and CEO, that it had been “working to assess all potential ways to maximize value for our shareholders, including liquidation, sale, merger, asset acquisitions, and/or continuing development of our internal programs.”

On this news, CymaBay stock dropped $0.21 per share, or over 11%, to close at $1.65 on January 30, 2020.

If you purchased or otherwise acquired CymaBay shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact  Melissa Fortunato or Marion Passmore or by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in CymaBay Therapeutics. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: